Brief: FDA Posts Warning Letter To Nutra Pharma For "Illegally" Marketing Unapproved Products

Nutra Pharma

19/03/2019 17:27

March 19 (Reuters) - FDA:
    * FDA TAKES ACTION AGAINST MARKETER OF UNAPPROVED PRODUCTS
CLAIMING TO TREAT ADDICTION, CHRONIC PAIN AND OTHER SERIOUS
CONDITIONS
    * FDA SAYS POSTED WARNING LETTER TO NUTRA PHARMA CORP FOR
ILLEGALLY MARKETING UNAPPROVED PRODUCTS
    * FDA -  ISSUED A WARNING LETTER TO NUTRA PHARMA FOR THEIR
PRODUCTS: “NYLOXIN ORAL SPRAY,” “NYLOXIN TOPICAL GEL,” “NYLOXIN
TOPICAL ROLL-ON,”
    * FDA -  ISSUED A WARNING LETTER TO NUTRA PHARMA FOR THEIR
PRODUCTS: “NYLOXIN TOPICAL ROLL-ON ES,” “NYLOXIN PROFESSIONAL
SIZE PUMP TOPICAL GEL”
    * FDA - FDA HAS REQUESTED RESPONSES FROM NUTRA PHARMA WITHIN
15
WORKING DAYS
    * FDA - ALSO ISSUED A WARNING LETTER TO NUTRA PHARMA FOR
PRODUCT:
“REGULAR STRENGTH SAMPLE PACK.”
    * FDA - WARNING LETTER TO NUTRA PHARMA STATES THAT FAILURE
TO
CORRECT VIOLATIONS MAY RESULT IN LEGAL ACTION WITHOUT FURTHER
NOTICE

Further company coverage:  NPHC.PK 

 ((Reuters.Briefs@thomsonreuters.com;))